Andrea Jackson is a Partner at Northpond Ventures. She joined Northpond in 2020 after 12 years of operating and finance roles in small and large scientific and technology companies. Andrea’s work at Northpond focuses on leading the people operations and portfolio management of the investment team. She is a board director at technology companies such as Outcomes4Me, Saama, Scitara, and VieCure; and R&D solutions companies, including Elephas Bio, Refeyn, Telesis Bio (NASDAQ: TBIO), Ultivue, and Vizgen. Andrea also served on the board at Current Health (acquired by Best Buy), DeepLens (acquired by Paradigm), and NanoView Biosciences (acquired by Unchained Labs).
Andrea’s previous operating roles spanned commercial, sales, product management, and operational roles at life science startups and large companies such as PerkinElmer (NYSE: PKI) and Millipore. Before her operating roles, Andrea worked in JPMorgan’s Healthcare Investment Banking team and focused on life science tools, diagnostics, and biotechnology companies. Andrea received an MBA from Kellogg School of Management at Northwestern University and a B.A. with honors from Washington University in St. Louis.
